8-K: AEON Biopharma Restates Financials Due to Calculation Errors, Raises Going Concern Doubts

AEON Biopharma has announced a restatement of its previously issued financial statements for the three and nine months ended September 30, 2023, due to calculation errors, and also expressed substantial doubt about its ability to continue as a going concern.

Summary

• AEON Biopharma's Audit Committee determined that the company's financial statements for the three and nine months ended September 30, 2023, should not be relied upon due to calculation errors.
• The errors primarily relate to valuation estimates of contingent consideration liability, convertible notes, stock-based compensation expense, and derivative liabilities.
• These errors resulted in a $22.7 million increase in losses for the Predecessor Period (January 1, 2023 to July 21, 2023) and a $6.4 million increase in income for the Successor Period (July 22, 2023 to September 30, 2023).
• The errors also increased the contingent consideration liability by approximately $6.7 million on the balance sheet at September 30, 2023.
• The company is still evaluating other non-cash items related to the merger and further revisions may be required.
• AEON Biopharma expects to report one or more material weaknesses in internal controls, in addition to a previously identified weakness.
• The company also anticipates disclosing substantial doubt about its ability to continue as a going concern for at least twelve months from the expected issuance date of the Form 10-K for the fiscal year ended December 31, 2023.
• The company intends to file restated unaudited interim financial statements as soon as practicable.

Sentiment

Score: 2

Explanation: The document reveals significant issues including a financial restatement, material weaknesses in internal controls, and substantial doubt about the company's ability to continue as a going concern. These factors indicate a very negative outlook from an investment perspective.

Negatives

• The company's previously issued financial statements for the three and nine months ended September 30, 2023, are unreliable.
• The company has identified errors in valuation estimates, leading to a restatement of financials.
• The restatement resulted in a significant increase in losses for the Predecessor Period.
• The company expects to report material weaknesses in internal controls.
• There is substantial doubt about the company's ability to continue as a going concern.

Risks

• The company faces the risk of legal proceedings.
• The company may not be able to meet continued stock exchange listing standards.
• The company faces costs related to being a public company.
• The company's ability to continue as a going concern is in doubt.
• Further revisions to the financial statements may be required.

Future Outlook

The company expects to file restated unaudited interim financial statements as soon as practicable and anticipates disclosing substantial doubt about its ability to continue as a going concern for at least twelve months from the expected issuance date of the Form 10-K for the fiscal year ended December 31, 2023.

Management Comments

• The Audit Committee concluded that the company's previously issued financial statements should no longer be relied upon.
• Management has discussed the matters with KPMG LLP, the company's independent registered public accounting firm.
• The company intends to file restated unaudited interim financial statements as soon as practicable.

Industry Context

This announcement highlights the importance of accurate financial reporting and internal controls, which are critical for maintaining investor confidence in the biotechnology sector. Restatements and going concern issues can significantly impact a company's valuation and future prospects.

Comparison to Industry Standards

• Restatements of financial statements are generally viewed negatively by investors and can lead to a loss of confidence in a company's management and financial reporting processes.
• Companies in the biotechnology sector, especially those in early stages of development, often face challenges in accurately valuing complex financial instruments such as contingent liabilities and derivatives.
• The disclosure of a going concern issue is a serious matter that can impact a company's ability to raise capital and continue operations. This is not uncommon for early stage biotech companies but is a significant risk factor.
• Comparible companies that have had similar issues include Cassava Sciences and Prothena, both of which have faced scrutiny over their financial reporting and internal controls.

Stakeholder Impact

• Shareholders will be negatively impacted by the restatement and the going concern issue.
• Employees may be concerned about the company's future viability.
• Creditors may be hesitant to extend credit to the company.
• Customers and suppliers may be concerned about the company's ability to fulfill its obligations.

Next Steps

• The company intends to file restated unaudited interim financial statements in an amendment to the Form 10-Q.
• The company will describe the identified errors and material weaknesses in an Explanatory Note to the Form 10-Q Amendment.
• The company will continue to assess its ability to continue as a going concern.

Key Dates

Keywords

financial restatement, material weakness, going concern, valuation errors, contingent consideration, convertible notes, stock-based compensation, derivative liabilities, internal controls, AEON Biopharma